Razor Genomics, Inc
Razor Genomics, Inc., based in Brisbane, CA, specializes in molecular stratification testing for patients with early-stage non-squamous non-small cell lung cancer (NSCLC). Their flagship product, RiskReveal, identifies patients at low- or high-risk of recurrence, providing vital information that aids oncologists in making informed decisions regarding adjuvant therapy.
Validated in multiple independent studies, RiskReveal analyzes a 14-gene molecular signature to effectively predict patient outcomes and enhance treatment options. The company's commitment to accessible and affordable testing solutions ensures that all patients, regardless of financial circumstances, can benefit from their innovative services.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.


